

## Special Issue

# Changing Landscape of Hereditary Breast and Ovarian Cancer

### Message from the Guest Editor

We are putting together a Special Issue to discuss emerging and recent updates surrounding the epidemiology and management of hereditary breast and ovarian cancers. Specifically, we are aiming to publish novel findings regarding the role of germline mutations in *BRCA1* or *BRCA2* and other genes in cancer risk and management. We are considering topics across the continuum, including the role of other cancer susceptibility genes, novel models of genetic testing, screening, prevention and treatment. We will consider both original research and timely reviews. Based on your expertise, we are inviting you to submit a review or original manuscript on the topic of *BRCA* Mutations among Breast and Ovarian Cancers. However, if you have an alternative topic that aligns with the summary or overall theme of this Special Issue, we welcome novel suggestions.

---

### Guest Editor

Dr. Joanne Kotsopoulos

1. Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada
2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada

---

### Deadline for manuscript submissions

closed (1 March 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/53592](https://mdpi.com/si/53592)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)